Developmental principles informing human pluripotent stem cell differentiation to cartilage and bone.

Semin Cell Dev Biol

Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK.

Published: July 2022

AI Article Synopsis

  • Human pluripotent stem cells can become any cell type and are key in studying early human tissue and disease development.
  • Researchers review the main biological pathways (neural crest, lateral plate mesoderm, and paraxial mesoderm) essential for cartilage and bone development.
  • The article also discusses advancements in differentiation methods using these stem cells to explore skeletal genetic diseases, enhancing our understanding of their origins and characteristics.

Article Abstract

Human pluripotent stem cells can differentiate into any cell type given appropriate signals and hence have been used to research early human development of many tissues and diseases. Here, we review the major biological factors that regulate cartilage and bone development through the three main routes of neural crest, lateral plate mesoderm and paraxial mesoderm. We examine how these routes have been used in differentiation protocols that replicate skeletal development using human pluripotent stem cells and how these methods have been refined and improved over time. Finally, we discuss how pluripotent stem cells can be employed to understand human skeletal genetic diseases with a developmental origin and phenotype, and how developmental protocols have been applied to gain a better understanding of these conditions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcdb.2021.11.024DOI Listing

Publication Analysis

Top Keywords

pluripotent stem
16
human pluripotent
12
stem cells
12
cartilage bone
8
human
5
developmental principles
4
principles informing
4
informing human
4
pluripotent
4
stem
4

Similar Publications

Autosomal-recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an early-onset neurodegenerative disease caused by mutations in the SACS gene. The first two mutations were identified in French Canadian populations 20 years ago. The disease is now known as one of the most frequent recessive ataxias worldwide.

View Article and Find Full Text PDF

A rapid chemical reprogramming system to generate human pluripotent stem cells.

Nat Chem Biol

January 2025

MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences and MOE Engineering Research Center of Regenerative Medicine, School of Basic Medical Sciences, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, China.

Chemical reprogramming enables the generation of human pluripotent stem (hCiPS) cells from somatic cells using small molecules, providing a promising strategy for regenerative medicine. However, the current method is time consuming, and some cell lines from different donors are resistant to chemical induction, limiting the utility of this approach. Here, we developed a fast reprogramming system capable of generating hCiPS cells in as few as 10 days.

View Article and Find Full Text PDF

Non-canonical roles of CFH in retinal pigment epithelial cells revealed by dysfunctional rare CFH variants.

Stem Cell Reports

December 2024

Department of Cardio Metabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. Electronic address:

Complement factor H (CFH) common genetic variants have been associated with age-related macular degeneration (AMD). While most previous in vitro RPE studies focused on the common p.His402Tyr CFH variant, we characterized rare CFH variants that are highly penetrant for AMD using induced pluripotent stem-cell-derived retinal pigment epithelium (iPSC-RPE).

View Article and Find Full Text PDF

Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update.

Cell Stem Cell

January 2025

Carpenter Consulting Corporation, Washington, USA. Electronic address:

Since the first derivation of human pluripotent stem cells (hPSCs) 27 years ago, technologies to control their differentiation and manufacturing have advanced immensely, enabling increasing numbers of clinical trials with hPSC-derived products. Here, we revew the landscape of interventional hPSC trials worldwide, highlighting available data on clinical safety and efficacy. As of December 2024, we identify 116 clinical trials with regulatory approval, testing 83 hPSC products.

View Article and Find Full Text PDF

Engineered hiPSC-derived vascular graft brings hope for thrombosis-free vascular therapy.

Cell Stem Cell

January 2025

Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI, USA. Electronic address:

Tissue-engineered vascular conduits (TEVCs) are a promising blood vessel replacement. In a recent publication in Cell Stem Cell, Park et al. developed TEVCs comprised of decellularized human umbilical arteries lined with shear-trained, human induced pluripotent stem cell (hiPSC)-derived endothelial cells (ECs) that resisted thrombosis and exhibited patency upon grafting into the rat inferior vena cava (IVC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!